A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
March 23, 2021
End Date
April 16, 2024
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
March 23, 2021
End Date
April 16, 2024